M G Franzosi

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. ncbi Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators
    M G Franzosi
    GISSI Coordinating Center, Milano and Ospedale Niguarda Cà Granda
    Circulation 98:2659-65. 1998
  2. ncbi Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial
    M G Franzosi
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Pharmacoeconomics 13:337-46. 1998
  3. ncbi Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    J Am Coll Cardiol 35:1801-7. 2000
  4. ncbi Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62 20157 Milan, Italy
    Heart Dis 2:185-90. 2000
  5. ncbi Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial
    M G Franzosi
    Department of Cardiovascular Research, Istituto di Richerche Farmacologiche Mario Negri, Milano, Italy
    Pharmacoeconomics 19:411-20. 2001
  6. ncbi Thrombolytic therapy in acute myocardial infarction
    M G Franzosi
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Thromb Haemost 3:2807-8. 2005
  7. doi Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan Istituti Ospitalieri, Cremona POL Madonna della Consolazione, Reggio Calabria, Italy
    J Intern Med 269:160-71. 2011

Detail Information

Publications8

  1. ncbi Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators
    M G Franzosi
    GISSI Coordinating Center, Milano and Ospedale Niguarda Cà Granda
    Circulation 98:2659-65. 1998
    ..We conducted a 10-year follow-up of the 11 712 patients with acute myocardial infarction randomized in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study, the first large trial assessing thrombolytic therapy...
  2. ncbi Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial
    M G Franzosi
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Pharmacoeconomics 13:337-46. 1998
    ..The cost effectiveness of early treatment with lisinopril of a relatively unselected population of patients with acute MI compares very favourably with that of other therapies judged to be worthwhile by the medical community...
  3. ncbi Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    J Am Coll Cardiol 35:1801-7. 2000
    ..We sought to determine whether the clinical effects of early angiotensin-converting enzyme (ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the concomitant use of aspirin (ASA)...
  4. ncbi Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62 20157 Milan, Italy
    Heart Dis 2:185-90. 2000
    ..Lisinopril is safe and effective when given early after the onset of myocardial infarction, regardless of a concomitant administration of ASA started early and continued over a 6-week period...
  5. ncbi Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial
    M G Franzosi
    Department of Cardiovascular Research, Istituto di Richerche Farmacologiche Mario Negri, Milano, Italy
    Pharmacoeconomics 19:411-20. 2001
    ..To estimate the cost effectiveness of treatment with n-3 polyunsaturated fatty acids (PUFA) for secondary prevention after myocardial infarction (MI)...
  6. ncbi Thrombolytic therapy in acute myocardial infarction
    M G Franzosi
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Thromb Haemost 3:2807-8. 2005
  7. doi Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan Istituti Ospitalieri, Cremona POL Madonna della Consolazione, Reggio Calabria, Italy
    J Intern Med 269:160-71. 2011
    ..we evaluated the prognostic role of circulating cardiovascular biomarkers in patients with a history of recent atrial fibrillation (AF)...